Pachyonychia congenita and botulinum toxin

Thomas, Barry; Sahota, A.

doi:10.1111/bjd.18784

Cited by 6 publications

(4 citation statements)

References 8 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Pachyonychia congenita (PC) is a rare autosomal dominant genodermatosis that is mainly characterized by plantar keratoderma, nail dystrophy, and plantar pain. Elevated ambient temperature, summer, and sweating aggravate this condition until disability [144]. In 2006, following this evidence, Swartling and Vahlquist [145] administered BoNT-A in 3 PC patients; the authors also reported not only an anhydrotic effect but also a great improvement in pain and discomfort since acitretin therapy was discontinued.…”

Section: Pachyonychia Congenitamentioning

confidence: 99%

Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review

Martina

Diotallevi

Radi

et al. 2021

Toxins

View full text Add to dashboard Cite

Botulinum toxin is a superfamily of neurotoxins produced by the bacterium Clostridium Botulinum with well-established efficacy and safety profile in focal idiopathic hyperhidrosis. Recently, botulinum toxins have also been used in many other skin diseases, in off label regimen. The objective of this manuscript is to review and analyze the main therapeutic applications of botulinum toxins in skin diseases. A systematic review of the published data was conducted, following Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Botulinum toxins present several label and off-label indications of interest for dermatologists. The best-reported evidence concerns focal idiopathic hyperhidrosis, Raynaud phenomenon, suppurative hidradenitis, Hailey–Hailey disease, epidermolysis bullosa simplex Weber–Cockayne type, Darier’s disease, pachyonychia congenita, aquagenic keratoderma, alopecia, psoriasis, notalgia paresthetica, facial erythema and flushing, and oily skin. Further clinical trials are still needed to better understand the real efficacy and safety of these applications and to standardize injection and doses protocols for off label applications.

show abstract

Section: Pachyonychia Congenitamentioning

confidence: 99%

Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review

Martina

Diotallevi

Radi

et al. 2021

Toxins

View full text Add to dashboard Cite

show abstract

“…54 Plantar injections with botulinum toxin type A have showed reduced keratoderma and plantar pain in PC-K6a and PC-K16, thought to be initiated through inhibition of sweating, and subsequent reduced epidermal damage, blistering, and pain. [55][56][57] However, it requires repeated and painful administrations requiring local anesthetic nerve block and reports are limited to small numbers. 55 Short interfering RNA approaches have been used successfully in hematology and have been used in PC via intralesional injection to selectively inhibit KRT6A to reduce plantar callus in a single patient in a split-body study.…”

Section: Future Management Optionsmentioning

confidence: 99%

Pachyonychia Congenita: Clinical Features and Future Treatments

Mccarthy,

De brito,

O’toole

2023

Keio J. Med.

View full text Add to dashboard Cite

Pachyonychia congenita (PC) is a rare, autosomal dominant inherited disorder of keratinization that is characterized by a triad of focal palmoplantar keratoderma, plantar pain, and hypertrophic nail dystrophy. It can be debilitating, causing significantly impaired mobility. PC is diagnosed clinically alongside identification of a heterozygous pathogenic mutation in one of five keratin genes: KRT6A, KRT6B, KRT6C, KRT16, or KRT17. Each keratin gene mutation is associated with a distinct clinical phenotype, with variable age of onset and additional features, which has allowed classification by genotype. Additional features include pilosebaceous cysts, follicular hyperkeratosis, natal teeth, oral leukokeratosis, hidradenitis suppurativa, itching, and neurovascular structures. Although classed as rare, the prevalence of PC is likely to be underestimated. There is no cure or specific treatment for PC at present. Current treatments are limited to conservative measures to reduce plantar friction and trauma, mechanical debridement, topical treatments, and treatments for associated features or complications, most commonly infection. However, through active research in collaboration with PC Project, a patient-advocacy group, and the International PC Research Registry, a global registry of PC patients, there are now many new potential therapeutic options on the horizon. This review summarizes the clinical features associated with PC and highlights the current and future treatment of its manifestations.

show abstract

“…Few researchers have concluded that BoNT-A injections not only improve hyperhidrosis, but it can also lead to reduction in pain and discomfort. 86 , 87 …”

Section: Role Of Bont In Dermatologymentioning

confidence: 99%

Utilities of Botulinum Toxins in Dermatology and Cosmetology

Naik¹

2021

CCID

View full text Add to dashboard Cite

Botulinum toxin (BoNT) is a neurotoxin produced by the Clostridium botulinum bacterium with a well-known efficacy and safety profile in the focal idiopathic hyperhidrosis treatment. BoNT comprises seven different neurotoxins; however, only toxins A and B are clinically employed. BoNT is lately practiced in off-label therapies for a variety of skin diseases. Scar prevention, hyperhidrosis, rhytides, eccrine nevus, alopecia, psoriasis, Darier disease, bullous skin disease, pompholyx and Raynaud’s phenomenon are some of the novel indications for BoNT in cosmetic and notably non-cosmetic aspects of dermatology. To employ BoNT correctly in clinical practice, we must have a thorough understanding of the functional anatomy of the mimetic muscles. An intensive literature search was conducted to update all dermatology-oriented experiments and clinical trials on the described element of BoNT for this general overview of BoNT use in dermatology. This review aims to analyse the role of BoNT in dermatology and cosmetology.

show abstract

Pachyonychia congenita and botulinum toxin

Abstract: Linked Article: Koren et al. Br J Dermatol 2020; 182:671–677.

Cited by 6 publications

References 8 publications

Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review

Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review

Pachyonychia Congenita: Clinical Features and Future Treatments

Utilities of Botulinum Toxins in Dermatology and Cosmetology

Contact Info

Product

Resources

About